as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹343.3
Change
-12.7 (-3.57%)
Open
₹354.3
Prev. Close
₹356.0
Day High
₹355.95
Day Low
₹340.0
Volume Analysis
Traded
37,699
Delivered
19,670
Delivery %
52.18%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (31.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year revenue growth (17.7%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹368.79 | ₹362.37 | ₹352.84 | ₹346.42 | ₹336.89 | ₹330.47 | ₹320.94 |
| Fibonacci | ₹362.37 | ₹356.28 | ₹352.51 | ₹346.42 | ₹340.33 | ₹336.56 | ₹330.47 |
| Camarilla | ₹347.69 | ₹346.22 | ₹344.76 | ₹346.42 | ₹341.84 | ₹340.38 | ₹338.91 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+25.68%
1 Week
-1.66%
1 Month
+0.91%
3 Months
+25.77%
6 Months
+39.97%
1 Year
+15.2%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹80.84
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
13.67%
Net margin 10.77% × asset turnover 0.69x × equity multiplier 1.84x
Company Overview
Sector
Healthcare
Market Cap
₹1,788 Cr
P/E (TTM)
49.9
ROE
14.2%
Book Value
₹47.0
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Suraksha Diagnostic Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 62/100. The strongest factor is Momentum (88/100), while Valuation (5/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (31.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
62/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 31.8% CAGR over last 5 years
- −Stock is trading at 7.30 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
21st AGM held on 22 Sept 2026; members approved financials, 0.50 dividend, and director reappointment.
21st AGM held on 22 Sept 2026; all resolutions passed, final dividend ₹0.50 per share declared.
The Newspaper Advertisement published on Monday, 31st August, 2026 with respect to the "Notice of 21st Annual General Meeting and e-voting information."
21st AGM on 22 September 2026; annual report sent, dividend record date 15 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 60 | 52 | 55 | 61 | 67 | 60 | 65 | 73 | 79 | 78 | 81 | 88 |
| Expenses + | 39 | 36 | 36 | 40 | 44 | 41 | 46 | 49 | 55 | 55 | 57 | 57 |
| Operating Profit | 21 | 15 | 19 | 21 | 23 | 18 | 19 | 24 | 24 | 23 | 24 | 30 |
| OPM % | 35.0% | 30.0% | 35.0% | 34.0% | 35.0% | 31.0% | 29.0% | 33.0% | 31.0% | 30.0% | 30.0% | 35.0% |
| Other Income + | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 |
| Depreciation | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | 10 | 11 | 11 | 11 |
| Profit before tax | 11 | 6 | 9 | 11 | 14 | 8 | 9 | 12 | 12 | 10 | 10 | 17 |
| Tax % | 24.0% | 27.0% | 32.0% | 27.0% | 26.0% | 26.0% | 22.0% | 26.0% | 27.0% | 28.0% | 38.0% | 22.0% |
| Net Profit + | 8 | 5 | 6 | 8 | 10 | 6 | 7 | 9 | 9 | 7 | 6 | 13 |
| EPS in Rs | 122 | 67 | 94 | 2 | 2 | 1 | 1 | 2 | 2 | 1 | 1 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 158 | 140 | 223 | 190 | 219 | 252 | 310 | 325 |
| Expenses + | 123 | 115 | 174 | 143 | 146 | 170 | 214 | 223 |
| Operating Profit | 34 | 25 | 49 | 47 | 73 | 82 | 96 | 102 |
| OPM % | 22.0% | 18.0% | 22.0% | 25.0% | 33.0% | 33.0% | 31.0% | 31.0% |
| Other Income + | 2 | -1 | 1 | 1 | 1 | 4 | 3 | 3 |
| Interest | 2 | 2 | 2 | 10 | 10 | 9 | 13 | 14 |
| Depreciation | 13 | 16 | 15 | 32 | 33 | 35 | 41 | 43 |
| Profit before tax | 21 | 6 | 33 | 7 | 31 | 41 | 45 | 49 |
| Tax % | 28.0% | -1.0% | 28.0% | 10.0% | 26.0% | 25.0% | 30.0% | — |
| Net Profit + | 15 | 6 | 24 | 6 | 23 | 31 | 31 | 35 |
| EPS in Rs | 220 | 93 | 344 | 94 | 342 | 6 | 6 | 7 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Reserves | 111 | 118 | 141 | 147 | 171 | 201 | 234 |
| Borrowings + | 13 | 18 | 21 | 99 | 92 | 89 | 130 |
| Other Liabilities + | 42 | 28 | 32 | 28 | 30 | 33 | 73 |
| Total Liabilities | 173 | 171 | 201 | 281 | 300 | 334 | 448 |
| Fixed Assets + | 128 | 119 | 119 | 195 | 212 | 223 | 315 |
| CWIP | 0 | 0 | 1 | 2 | 1 | 11 | 37 |
| Investments | 5 | 5 | 0 | 0 | 0 | 1 | 0 |
| Other Assets + | 39 | 46 | 80 | 84 | 87 | 99 | 97 |
| Total Assets | 173 | 171 | 201 | 281 | 300 | 334 | 448 |
| Equity Capital | 7 | 7 | 7 | 7 | 7 | 10 | 10 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 31 | 24 | 42 | 44 | 60 | 63 | 82 |
| Cash from Investing Activity + | -20 | -28 | -44 | -21 | -35 | -40 | -52 |
| Cash from Financing Activity + | -10 | 3 | 1 | -24 | -25 | -24 | -29 |
| Net Cash Flow | 1 | -1 | 0 | -1 | 0 | 0 | 1 |
| CFO/OP | 111 | 100 | 95 | 109 | 95 | 90 | 99 |
| Free Cash Flow | 15 | 8 | 23 | 32 | 18 | 21 | 15 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|
| Public | 15.39% | 14.71% | 14.79% | 15.3% | 14.98% | 14.31% | 14.2% |
| Promoters | 48.78% | 48.78% | 48.89% | 48.98% | 49.0% | 49.1% | 49.1% |
| FII | 15.39% | 14.46% | 13.95% | 13.73% | 13.46% | 13.46% | 13.47% |
| DII | 20.43% | 22.05% | 22.37% | 21.98% | 22.57% | 23.14% | 23.22% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Suraksha Diagnostic Ltd (this stock) | 1,788 | 49.9 | 7.3 | 14.2% |
| Krsnaa Diagnostics Ltd | 1,785 | 18.3 | 1.81 | 10.9% |
| Ngl Fine Chem Limited | 1,796 | 31.4 | 5.45 | 17.4% |
| Tarsons Products Limited | 1,770 | 150.0 | 2.8 | 2.44% |
| Hester Biosciences Ltd | 1,884 | 35.5 | 5.24 | 15.9% |
| Syncom Formu (i) Ltd | 1,885 | 22.0 | 4.54 | 17.6% |
| Anlon Healthcare Limited | 1,655 | 52.3 | 7.18 | 18.4% |
Which Mutual Funds Hold Suraksha Diagnostic Ltd?
Frequently Asked Questions about Suraksha Diagnostic Ltd
Suraksha Diagnostic Ltd (SURAKSHA) closed at ₹343.3 on NSE on 25 September 2026, down 12.7 (3.57%) from the previous close.
Suraksha Diagnostic Ltd trades on the NSE (National Stock Exchange of India) under the symbol SURAKSHA.
Suraksha Diagnostic Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 49.9.
Suraksha Diagnostic Ltd has a dividend yield of 0.15%.
Suraksha Diagnostic Ltd's 52-week high is ₹360.0 and its 52-week low is ₹224.0.
Suraksha Diagnostic Ltd has a market capitalisation of ₹1,788 crore.
Suraksha Diagnostic Ltd has a TopFund Quality Score of 62/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Suraksha Diagnostic Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.